A record of what Kotak Institutional Equities Analysis said publicly, with the source. Not advice.
“Kotak Institutional Equities maintains an optimistic outlook on the Indian pharma sector, believing high US tariffs on pharmaceuticals are improbable and unfeasible. They favor companies like Sun Pharmaceuticals, Cipla, Lupin, J.B. Chemicals and Pharmaceuticals, and Emcure Pharmaceuticals, citing India's significant role in supplying US generic drugs and biosimilars, and the low value impact of Indian generics on the overall US pharma market.”
Kotak Institutional Equities Analysis’s track record (trackable calls only): 40 graded calls · 95% CI 29–58%
How this relative call is judged
A relative call is a comparison, judged on closing prices from the first close after the call to the end of its window (3 months when the quote states no time frame). The spread is the pick's return minus the comparator's return: above zero is a hit for a call that favours the pick, and the reverse for a call that marks it down.
Window still open: no verdict until it ends.
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.
Read the original articleSee Kotak Institutional Equities Analysis’s full track record